SCHEMBL3566089

SCHEMBL3566089

NC(=O)N(c1ccc(Cl)cc1)C(C(=O)Nc1ccc(-c2cccc[n+]2[O-])cc1)c1ccccc1Oc1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PCTP Q9UKL6 2/20 0.36
XIAP P98170 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
PNLIP P16233 1/20 0.34
ALDH1A1 P00352 5/20 0.33
L3MBTL1 Q9Y468 3/20 0.33
GAA P10253 3/20 0.33
NPSR1 Q6W5P4 2/20 0.33
ATM Q13315 2/20 0.33
UTS2R Q9UKP6 1/20 0.33
NPY5R Q15761 1/20 0.33
GPR55 Q9Y2T6 1/20 0.33
TDP1 Q9NUW8 2/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
P2RY1 P47900 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.32
HTT P42858 2/20 0.32
CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3560706 0.91 PCTP (0.45) PCTPMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL3561429 0.88 PCTP (0.36) PCTPMEN1KMT2APNLIPALDH1A1
SCHEMBL3560098 0.87 PCTP (0.41) PCTPMEN1KMT2AALDH1A1GAA
SCHEMBL3559162 0.85 PCTP (0.35) PCTPMEN1KMT2AALDH1A1GAA
SCHEMBL3562244 0.85 PCTP (0.35) PCTPMEN1KMT2AALDH1A1GAA
SCHEMBL3557408 0.85 PCTP (0.35) PCTPMEN1KMT2AALDH1A1GAA
SCHEMBL3568267 0.85 PCTP (0.35) PCTPMEN1KMT2AALDH1A1GAA
SCHEMBL3576233 0.83 MEN1 (0.40) PCTPMEN1KMT2AALDH1A1GAA
SCHEMBL3560465 0.81 PCTP (0.34) PCTPMEN1KMT2AGAAATM
SCHEMBL3566091 0.80 UTS2R (0.41) PCTPXIAPMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 PCTP 1942/4885XIAP 2070/4885MEN1 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.